Loading...
CSL Limited
CSL.AX•ASX
Healthcare
Biotechnology
A$264.05
A$-6.85(-2.53%)
CSL Limited (CSL.AX) Financial Performance & Income Statement Overview
Review CSL Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-24.99%
↓ 24.99%
Operating Income Growth
-57.73%
↓ 57.73%
Net Income Growth
-20.81%
↓ 20.81%
Operating Cash Flow Growth
-27.27%
↓ 27.27%
Operating Margin
20.83%
↑ 20.83%
Gross Margin
49.14%
↑ 49.14%
Net Profit Margin
18.41%
↑ 18.41%
ROE
15.37%
↑ 15.37%
ROIC
9.63%
↑ 9.63%
CSL Limited (CSL.AX) Income Statement & Financial Overview
Review CSL Limited's (CSL.AX) income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $8.21B | $6.76B | $8.36B | $5.92B |
| Cost of Revenue | $3.93B | $3.68B | $4.07B | $3.29B |
| Gross Profit | $4.28B | $3.08B | $4.29B | $2.63B |
| Gross Profit Ratio | $0.52 | $0.46 | $0.51 | $0.44 |
| R&D Expenses | $646.00M | $769.94M | $699.10M | $647.34M |
| SG&A Expenses | $1.18B | $1.17B | $903.61M | $1.17B |
| Operating Expenses | $4.28B | $1.94B | $1.60B | $1.82B |
| Total Costs & Expenses | $8.21B | $5.62B | $5.68B | $5.10B |
| Interest Income | $18.00M | $19.25M | $20.87M | $3.24M |
| Interest Expense | $213.00M | $224.90M | $265.03M | $234.26M |
| Depreciation & Amortization | $476.00M | $515.66M | $447.63M | $441.88M |
| EBITDA | $3.23B | $1.75B | $3.19B | $1.36B |
| EBITDA Ratio | $0.39 | $0.26 | $0.37 | $0.21 |
| Operating Income | $0.00 | $1.14B | $2.69B | $816.13M |
| Operating Income Ratio | $0.00 | $0.17 | $0.32 | $0.14 |
| Other Income/Expenses (Net) | $2.54B | -$132.71M | -$204.51M | -$128.29M |
| Income Before Tax | $2.54B | $1.009B | $2.48B | $687.84M |
| Income Before Tax Ratio | $0.31 | $0.15 | $0.30 | $0.12 |
| Income Tax Expense | $484.00M | $204.64M | $478.94M | $94.27M |
| Net Income | $2.007B | $750.69M | $1.98B | $593.56M |
| Net Income Ratio | $0.24 | $0.11 | $0.24 | $0.10 |
| EPS | $4.15 | $2.33 | $4.11 | $1.23 |
| Diluted EPS | $4.13 | $2.32 | $4.09 | $1.22 |
| Weighted Avg Shares Outstanding | $483.25M | $483.25M | $482.83M | $482.37M |
| Weighted Avg Shares Outstanding (Diluted) | $485.75M | $485.75M | $484.98M | $484.59M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan